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Abstract
The full identiﬁcation and susceptibility proﬁle of staphylococci from positive blood cultures (BCs) generally takes 24–48 h using pheno-
typic methods. The aim of this prospective study was to evaluate the clinical impact of a real-time PCR strategy for rapid identiﬁcation
of staphylococci and determination of methicillin resistance directly from positive BCs. During a 12-month period, 250 episodes of posi-
tive BCs with organism morphology resembling staphylococci were enrolled. Two strategies were compared: conventional (n = 128)
using standard phenotypic methods or rapid (n = 122) using a real-time PCR assay that is able to detect speciﬁc genes of Staphylococcus
aureus (nuc and sa442) and the encoding gene for methicillin resistance (mecA). Overall, 97 episodes (39%) were clinical-signiﬁcant
bloodstream infections. The prevalence of methicillin resistance of S. aureus was 24%. A favorable outcome (deﬁned as clinical cure with
resolution of signs and no evidence of recurrence or relapse at 12 weeks follow-up) was observed in similar proportions of episodes
with (58%) or without (60%) PCR testing (p 0.8). In multivariate analyses, age and infection due to methicillin-susceptible S. aureus
(adjusted OR 0.96, 95% CI 0.93–0.99; and adjusted OR 3.11, 95% CI 1.12–8.65, respectively) were the unique factors independently
associated with a favorable outcome. Among the 153 episodes of contaminated BCs, similar proportions received unjustiﬁed antibiotic
therapy (PCR strategy: 17%, conventional testing: 10%; p 0.33). In a setting with a moderate level of methicillin-resistant S. aureus and
relatively high contamination of BCs, real-time PCR testing was not beneﬁcial compared to conventional methods.
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Introduction
Staphylococci are the dominant species recovered from posi-
tive blood cultures (BCs) [1]. The species Staphylococcus aur-
eus is the leading cause of community-acquired and
nosocomial bloodstream infection (BSI) and is associated with
a high mortality rate, whereas coagulase-negative staphylo-
cocci (CoNS) are often dismissed as contaminants [2–4]. The
differentiation between S. aureus and CoNS in blood cultures
is therefore very important. The second important question
that arises is whether that isolate is susceptible to methicillin
or not. Indeed, BSI caused by methicillin-susceptible S. aureus
(MSSA) should be preferably treated with b-lactam antibiotics
rather than glycopeptides because of a higher clinical efﬁcacy
and lower toxicity [5]. On the other hand, the administration
of inadequate antimicrobial therapy for BSI due to MRSA is
associated with an increased mortality rate [6,7].
In clinical microbiology laboratories, after a BC bottle is
ﬂagged as positive by the BC instrument, identiﬁcation and
antimicrobial susceptibility testing generally takes 24–8 h
using standard phenotypic methods. Recently, molecular
PCR-based methods have been described for identifying
S. aureus by using different targets and for detecting resis-
tance to methicillin in staphylococci encoded by the mecA
gene [8–14].
Rapid reporting of infection and susceptibility results may
signiﬁcantly improve outcomes by enabling rapid adjustment
of antimicrobial therapy, leading to decreased mortality,
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE INFECTIOUS DISEASES
shortened hospital stay and lower hospitalization costs [15–
17]. Despite the availability of real-time PCR-based tech-
niques, the clinical impact of rapid S. aureus identiﬁcation and
mecA detection has not been yet demonstrated [18,19].
In the present study, we evaluated the clinical impact of a
real-time PCR assay for the rapid identiﬁcation of S. aureus
and detection of methicillin resistance by comparison with a
conventional strategy using standard phenotypic methods.
Materials and Methods
Patients and study design
This study was conducted at Henri Mondor Hospital, a
900-bed teaching hospital in Cre´teil, France. We followed the
recommendations of the STROBE statement for reporting the
results of the observational studies. The Institutional Review
Board approved the study protocol and waived the require-
ment for informed consent. During a 12-month period, we
prospectively enrolled all adult inpatients, including emergency
patients, suspected of having staphylococcal BSI (deﬁned as
patients with ‡1 BC positive for Gram-positive cocci in
cluster). Patients with neutropaenia were not included. For
reasons of practicality, only BCs becoming positive between
17.00 h and 10.00 h during weekdays were included. The unit
of the analysis was the episode of positive BC and not the
patient because patients could be enrolled twice if there was
an interval of at least 1 month between the two episodes.
Demographic and clinical data were obtained for all
patients, including the severity of infection assessed by the
SOFA score [20], as well as the nature of antibiotic treat-
ment (including modalities of administration, dosage and
duration). Catheter-related infection and endocarditis were
diagnosed according to the Infectious Diseases Society of
America guidelines and the modiﬁed Duke criteria [21,22].
All patients were prospectively followed up for 3 months
after enrolment.
The conventional strategy was used 3 days a week for the
ﬁrst 6 months and 2 days a week for the last 6 months. Pre-
liminary BC results (Gram stain results) were reported by
telephone to clinicians before 12.00 h following a pre-deﬁned
algorithm. Final identiﬁcation and susceptibility results were
later available via the Intranet. The PCR strategy was used
2 days a week for the ﬁrst 6 months and 3 days a week for
the last 6 months, and the results (including Gram stain
results, identiﬁcation of staphylococci and determination of
methicillin resistance) were telephoned before 12.00 h with
another algorithm. Identiﬁcation of S. aureus in at least one
BC was considered to comprise a BSI to be treated with
intravenous oxacillin or vancomycin according to the PCR
result. Identiﬁcation of CoNS in a single BC was considered
to comprise a contaminant. When CoNS was identiﬁed in at
least two two BCs, it was also considered as a contaminant
if the patient had no endocarditis or catheter-related infec-
tion. Treating patients with CoNS contaminated BC was
strongly discouraged.
Conventional identiﬁcation and antimicrobial susceptibility
testing
Blood samples obtained for culture were inoculated into aer-
obic and anaerobic BC bottles using BacT/ALERT blood cul-
ture system (bioMe´rieux, Marcy-l’Etoile, France). All positive
BCs (including those tested by PCR) were plated on routine
culture media for the identiﬁcation of Gram-positive cocci
isolates. Staphylococcal isolates were phenotypically identi-
ﬁed by colony morphology, catalase reaction, thermonuc-
lease production and, if necessary, coagulase production and
results of the API STAPH system (bioMe´rieux).
Resistance to methicillin was detected by cefoxitin disk
diffusion performed on Mueller–Hinton agar according to the
Antibiogram Committee of the French Society for Microbiol-
ogy (http://www.sfm.asso.fr/). For ambiguous cases, PBP-2a
detection using the PBP2¢ latex agglutination test kit (Oxoid,
Basingstoke, UK) was performed.
Real-time PCR assay
Rapid DNA extraction from Gram-positive cocci in cluster-
positive BCs was performed after separation of the charcoal
and the bacteria by differential centrifugation, as described
previously [11]. Real-time PCR assays were performed using
the LightCycler system, version 2.0 (Roche Diagnostics,
Meylan, France) and molecular identiﬁcation of S. aureus was
achieved by ampliﬁcation of two speciﬁc genes, sa442 and
nuc (Table 1). Detection of methicillin resistance was carried
out using two sets of primers able to amplify two different
regions of the mecA gene (mecA-1 and mecA-2) (Table 1).
The PCR assay using primers and probes (sa442 and mecA-1)
was evaluated previously [11] and was improved further with
additional primers and probes (nuc and mecA-2) and initially
tested on 173 BCs (V. Cattoir, L. Bait-merabet, J.-M. Le
Glaunec, N. Launay, P. Legrand, unpublished data). This latter
technique was found to be 100% speciﬁc and sensitive for
the identiﬁcation of S. aureus, 100% speciﬁc and sensitive for
the detection of methicillin resistance in S. aureus, and 100%
speciﬁc and 95% sensitive for the detection of methicillin
resistance in CoNs.
Antibiotic treatment and clinical outcome
The clinical outcome of patients with BSI at the 12 weeks
follow-up visit was deﬁned as favourable when there was
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resolution of clinical signs of infection during therapy and no
evidence of recurrent staphylococcal infection. It was consid-
ered unfavourable in cases of relapse or death. In addition,
the adequacy of antimicrobial therapy for BSI episodes was
analyzed using the criteria: (i) time to initiation of active anti-
microbial therapy (deﬁned as the delay between time of
reporting BC results by the microbiological laboratory to the
ward physician and the start of antibiotic therapy that include
a drug active against the isolated pathogen) and (ii) percent-
age of episodes receiving an optimal treatment (deﬁned as
receiving oxacillin for methicillin-susceptible staphylococci or
vancomycin for methicillin- resistant staphylococci) on the
day after reporting results by the microbiological laboratory
to the ward physician. Time to initiation of active antimicro-
bial therapy was also assessed by comparing the delay
between the ﬁnal identiﬁcation of staphylococci and the start
of therapy and the delay between blood culture sampling and
the start of therapy.
For contaminated BCs, we also evaluated the proportion
of episodes receiving unjustiﬁed antibiotic therapy.
Statistical analysis
A chi-square test or Fisher’s exact test was used, as appro-
priate, to compare categorical variables. The Mann–Whitney
nonparametric test was used to compare continuous vari-
ables. Each factor potentially associated with a favourable
outcome was tested in a univariate model. Factors with a
p <0.10 in univariate analysis were then entered in a logistic
regression model and PCR testing was forced into the
model. Variables were not dichotomized. Goodness of ﬁt
was assessed using the Hosmer–Lemeshow chi-square test,
and discrimination was determined from the area under the
receiver operating characteristics curve. The adjusted OR
and 95% CI were calculated for each factor that was statisti-
cally signiﬁcant in the logistic regression model. p <0.05 was
considered statistically signiﬁcant. All tests were two-tailed.
Statistical tests were performed using Intercooled STATA
software, version 8.2 (StataCorp, College Station, TX, USA).
Results
From January 2006 to January 2007, a total of 250 BCs posi-
tive for staphylococci were reported in 241 patients. The
study included 128 and 122 episodes analyzed by conven-
tional and PCR strategies, respectively. The distribution of
BSI and contaminant episodes and pathogens is shown in
Fig. 1. MRSA were found in 16 (24%) of BSI episodes caused
by S. aureus. Of the episodes deﬁned as a contamination,
S. aureus was detected in a single BC from a patient with
severe cutaneous disease and heavy S. aureus colonization
(1%) (Fig. 1).
Of the BSI episodes, 49 were in the PCR testing group,
whereas 48 were in the conventional testing group (Table 2).
Baseline demographic, clinical and microbiological character-
istics were comparable in both study groups, although
patients were slightly older (p 0.099) and signiﬁcantly more
severe (as classiﬁed according to the SOFA score) in the
PCR testing group (Table 2). The results of the molecular
assay (n = 122) were in accordance with those of the pheno-
typic method for 100% of the strains.
A favourable outcome was observed in 61% of episodes
who had a PCR test compared to 73% of those who had con-
ventional testing (OR 0.59, 95% CI 0.25–1.38; p 0.221). There
was no difference in the rate of metastatic complication
between the PCR (10%) and the conventional (8%) groups
(OR 1.28, 95% CI 0.32–5.09; p 0.726). Median time to
defervescence was also similar in the two groups (Table 3).
TABLE 1. Primers and probes used in the present study
Oligonucleotides Sequence (5¢ to 3¢)
Target
gene
GenBank
accession no.
Nucleotide
position
Reference or
source
sa442-F GTCGGGTACACGATATTCTTCACG sa442 AF033191 12–34 9,11
sa442-R CTCTCGTATGACCAGCTTCGGTAC sa442 AF033191 191–168 9,11
sa442-HP-1 TACTGAAATCTCATTACGTTGCATCGGAA[Fluo] sa442 AF033191 95–123 9,11
sa442-HP-2 [Red705]ATTGTGTTCTGTATGTAAAAGCCGTCTTG[Phos] sa442 AF033191 126–154 9,11
nuc-F GTTGTAGTTTCAAGTCTAAG nuc BA000017 145–164 Present study
nuc-R TATCACCATCAATCGCT nuc BA000017 301–285 Present study
nuc-HP-1 CGGCGTAAATAGAAGTGGT[Fluo] nuc BA000017 195–213 Present study
nuc-HP-2 [Red640]TGAAGATCCAACAGTATATAGTGCAACTTCAA[Phos] nuc BA000017 216–247 Present study
mecA-1-F CAAGATATGAAGTGGTAAATGGT mecA X52593 1471–1493 9,11
mecA-1-R TTTACGACTTGTTGCATACCATC mecA X52593 1879–1857 9,11
mecA-1-HP-1 CAGGTTACGGACAAGGTGAAATACTGATT[Fluo] mecA X52593 1690–1718 9,11
mecA-1-HP-2 [Red640]ACCCAGTACAGATCCTTTCAATCTATAGCG[Phos] mecA X52593 1720–1739 9,11
mecA-2-F CAATACAATCGCACATACATTAATAGAGA mecA X52593 1058–1086 Present study
mecA-2-R CTCATGCCATACATAAATGGATAGAC mecA X52593 1267–1242 Present study
mecA-2-HP-1 AATGATTATGGCTCAGGTACTGCTATCC[Fluo] mecA X52593 1164–1191 Present study
mecA-2-HP-2 [Red705]CCTCAAACAGGTGAATTATTAGCACTTGTAAGCAC[Phos] mecA X52593 1194–1228 Present study
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Similarly, no signiﬁcant difference in favourable outcome was
observed at 12 weeks follow-up (PCR testing: 58%, conven-
tional testing: 60%; OR 0.84, 95% CI 0.37–1.90; p 0.68).
Table 3 shows the factors potentially associated with a
favourable outcome by univariate analysis. The six variables
with p <0.10 (i.e. age, absence of comorbidity, SOFA score,
infection due to MSSA, duration of antibiotic treatment, and
metastatic complication) were introduced into a regression
logistic model along with PCR testing. Only a younger age
and a bactaeremia due to MSSA were then found to be inde-
pendent factors associated with a favourable outcome
(Table 4). Surprisingly, the median time to initiation of appro-
priate antimicrobial therapy for BSI assessed by the delay
between reporting BC results by the microbiological labora-
tory to the ward physician and the start of therapy was not
signiﬁcantly different in the two groups (Table 2). Similarly,
the proportion of optimal treatment on the day after report-
ing results by the microbiological laboratory to the ward
physician was the same between the two groups (Table 2).
However, rapid identiﬁcation of staphylococci and methicillin
Positive blood
culture episodes
(n = 250)
BSI episodes
39% (n = 97)
Contaminants
episodes
(n = 153)
S. aureus
70% (n = 68)
CoNS
30% (n = 29)
S. aureus
1% (n = 1)
CoNS
99% (n = 152)
MSSA
76% (n = 52)
MRSA
24% (n = 16)
MSCoNS
24% (n = 7)
MRCoNS
72% (n = 21)
MSSA
(n = 1)
MSCoNS
31.5% (n = 48)
MRCoNS
50% (n = 76)
MR/SCoNS
4%  (n = 1)
MR/SCoNS
18.5% (n = 28)
FIG. 1. Classiﬁcation of the episodes of staphylococcal-positive blood cultures by type of isolate. BSI, bloodstream infection; CoNS, coagulase-
negative staphylococci; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus; MRCoNS, methicillin-resistant
CoNS; MSCoNS, methicillin-susceptible CoNS; MR/ScoNS, mixture of methicillin-resistant and -susceptible CoNS.
TABLE 2. Baseline demographic and clinical characteristics of patients with BSI
Characteristic
PCR testing
group (n = 49)
Conventional testing
group (n = 48) OR (95% CI) p value
Age (years) 62 (57–76) 61 (45–71) 1.02 (1.00–1.05) 0.099
Male gender, n (%) 35 (67) 32 (67) 1.25 (0.53–2.96) 0.612
Presence of signiﬁcant comorbidity, n (%) 39 (80) 35 (73) 1.30 (0.50–3.37) 0.440
Presence of intravascular catheter, n (%) 37 (76) 34 (71) 1.27 (0.52–3.13) 0.603
Nosocomial BSI, n (%) 37 (76) 36 (75) 1.03 (0.41–2.59) 0.954
Severe sepsis or septic shock, n (%) 11 (22) 6 (13) 2.03 (0.68–6.01) 0.198
Duration of sepsis symptoms (h) 2 (1–4) 1 (1–4) 1.02 (0.95–1.10) 0.567
SOFA score (points) 4 (2–6) 2 (1–4) 1.15 (1.06–1.24) 0.015
Focus of infection, n (%)
Intravascular catheter 18 (44) 21 (54) – 0.117
Soft and skin tissue 18 (44) 8 (20)
Other 5 (12) 10 (26)
Pathogen identiﬁed, n (%)
MSSA 29 (59) 23 (48) – 0.612
MRSA 9 (19) 8 (17)
MSCoNS 3 (6) 4 (8)
MRCoNS 8 (16) 12 (25)
MSCoNS and MRCoNS 0 (0) 1 (2)
Focus of infection removed, n (%) 28 (62) 34 (76) 0.53 (0.21–1.32) 0.172
Appropriate empirical antibiotic therapy, n (%)a 20 (40) 18 (37) 1.19 (0.52–2.70) 0.676
Time to initiation of appropriate therapy (h)b 1 (0–5) 3 (0–19) 0.99 (0.96–1.01) 0.443
Time to initiation of appropriate therapy after ﬁnal identiﬁcation of staphylococci (h) 4 (0–8) 27 (0–43) 0.96 (0.94–0.99) 0.012
Time to initiation of appropriate therapy after blood culture sampling, hours 25 (0–48) 26 (0–50) 0.99 (0.98–1.01) 0.814
Time between BC sampling and results reporting (h) 24 (24–48) 24 (24–24) 1.03 (1.01–1.06) 0.029
Optimal treatment, n (%)c 38 (78) 37 (77) 1.03 (0.36–2.94) 0.956
Duration of antibiotic treatment (days) 14 (11–26) 14 (9–19) 1.02 (0.99–1.05) 0.330
Results are expressed as median and interquartile range unless otherwise indicated.
BSI, bloodstream infection; MSSA, Methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus; MSCoNS, Methicillin-susceptible CoNS; MRCoNS, Methi-
cillin-resistant CoNS.
aPatients receiving antibiotic therapy that include a drug active against the isolated pathogen before reporting blood culture results.
bDelay between time of reporting blood culture results by the microbiological laboratory to the ward physician and the start of antibiotic therapy that include a drug active
against the isolated pathogen.
cPatients receiving either methicillin for MSSA and MSCoNS, or vancomycin for MRSA and MRCoNS, on the day after reporting results.
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resistance by PCR was associated with a signiﬁcant shorter
delay between the time of ﬁnal identiﬁcation and the start of
active antibiotic therapy (Table 2).
Among the 153 episodes of contaminated BCs, 17% of
those in the PCR testing group received unjustiﬁed antibiotic
therapy compared to 10% of those in the conventional test-
ing group (OR 1.77, 95% CI 0.62–5.12; p 0.237). Following
PCR identiﬁcation of CoNS contaminants, anti-staphylococcal
antibiotics were stopped in eight of 12 episodes in the PCR
testing group and three of eight episodes in the conventional
testing group (p 0.361).
Discussion
Several studies have shown the ability of genotypic methods
to rapidly detect S. aureus and methicillin resistance [9–14].
However, improvement of treatment effectiveness has
only been described in retrospective studies [10,19,23]. By
contrast, only a single prospective study has been conducted
to evaluate the clinical impact (in terms of outcome of the
infection or general clinical outcome) of a PCR assay directly
from BCs positive for Gram-positive cocci in cluster [18]. In
that study, rapid identiﬁcation of S. aureus and determination
of oxacillin susceptibility by using a PCR assay did not have a
major clinical impact for intensive care unit patients suffering
from S. aureus BSI [18]. In the present investigation, our
real-time PCR assay was conﬁrmed to be as accurate as con-
ventional methods but there was no signiﬁcant difference
between the two methods in terms of clinical outcome, sup-
porting the previous study [18]. Indeed, the impact of initial
antibiotic choice on the outcome of BSI caused by S. aureus
remains a subject of debate. Some studies have found
that inappropriate initial therapy is associated with higher
in-hospital mortality and that initial vancomycin for MSSA
bacteremia may delay the clearance of S. aureus from blood
[24]. By contrast, a recent study showed that inadequate
empirical antimicrobial therapy for S. aureus BSI was not
associated with an increased 30-day mortality rate [25].
On the other hand, rapid differentiation of S. aureus from
CoNS may be useful for the management of contaminated
BCs with CoNS by preventing unnecessary usage of antibiot-
ics, specially vancomycin, and reducing hospital stay and cost
[26]. However, in the present study, there was a smaller
proportion of patients with contaminated blood cultures
who received unjustiﬁed antibiotic therapy (PCR strategy:
17%, conventional testing: 10%) compared to the percentage
of patients receiving vancomycin in a previous study (PCR
strategy: 91%, conventional strategy: 83%) [26].
The present study has some limitations that may explain
the lack of evidence of a global clinical beneﬁt. First, there
were only 16 BSI episodes caused by MRSA. This may be
related to the appropriate infection control program rou-
tinely performed in our hospital, which includes selective
screening of MRSA, a signiﬁcant factor of decreasing risk for
MRSA BSI [27]. Second, a large proportion of patients (39%)
had active antimicrobial treatment before the BC results
were available. The importance of this latter point has been
TABLE 4. Factors independently associated with a favorable
outcome
Variable
Adjusted
OR 95% CI p value
Age 0.96 0.93–0.99 0.037
Absence of comorbidity 2.12 0.49–9.12 0.314
SOFA score 0.89 0.79–1.01 0.075
Methicillin-susceptible Staphylococcus aureus 3.11 1.12–8.65 0.029
Duration of antibiotic treatment 1.03 0.98–1.08 0.225
Metastatic complication 0.52 0.15–1.85 0.313
PCR testing 0.63 0.22–1.77 0.380
Performance of the model, Hosmer–Lemeshow goodness-of-ﬁt; p 0.281; area
under receiver operating characteristics curve, 0.793.
TABLE 3. Factors potentially associ-
ated with a favourable outcome at
hospital discharge
Factor
Favourable outcome
(n = 65)
Unfavourable outcome
(n = 32) p value
Age, years 61 (47–71) 66 (56–77) 0.094
Male gender, n (%) 48 (74%) 19 (59%) 0.147
Absence of comorbidity, n (%) 20 (31%) 3 (9%) 0.023
Presence of intravascular catheter, n (%) 49 (75%) 22 (69%) 0.488
Nosocomial BSI, n (%) 49 (75%) 24 (75%) 0.967
SOFA score (points) 2 (1–4) 3 (2–6) 0.065
Duration of sepsis symptoms (h) 1 (1–3) 2 (1–4) 0.562
Methicillin-susceptible Staphylococcus, n (%) 45 (69%) 14 (44%) 0.016
Focus of infection removed, n (%) 46 (72%) 16 (62%) 0.337
Metastatic complication, n (%) 3 (5%) 6 (19%) 0.056
Duration of antibiotic treatment (days) 14 (12–24) 13 (6–16) 0.016
Time to defervescence (days) 2 (1–3) 2 (1–4) 0.308
Negative blood culture at day 7 47 (72%) 18 (56%) 0.114
PCR testing 30 (44%) 19 (57%) 0.221
BSI, bloodstream infection.
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highlighted in a previous study, where only 25% of patients
beneﬁted from a modiﬁcation of antimicrobial therapy based
on the PCR results because empirical therapy was appropri-
ate in the majority of cases [19]. Third, the lack of difference
between the PCR and conventional groups might be due to
the fact that, in our hospital, physicians generally follow the
advice of clinical microbiologists and infectious diseases con-
sultants, and such compliance can improve the clinical out-
come for patients with S. aureus bacteraemia [28]. This was
illustrated by the very short delay before initiation of active
antimicrobial therapy following the report of the BC results
observed in both groups. This real-time PCR assay showed
limited clinical beneﬁts in our setting, although the usefulness
might be higher in other institutions with a higher prevalence
of MRSA (especially community-acquired MRSA) or less fre-
quently appropriate empirical therapy [10]. Finally, the pres-
ent study has the limitation of being a single-center,
nonblinded and nonrandomized design.
In conclusion, this prospective study evaluating the clinical
impact of a real-time PCR assay for identiﬁcation of S. aureus
and determination of methicillin resistance did not show a clin-
ical beneﬁt compared to conventional phenotypic methods in
our hospital setting. Employment of faster molecular methods
directly from the blood of septic patients (without preculture)
is likely to have a beneﬁcial clinical impact because the time to
BC positivity (especially <12–14 h) in S. aureus bacteraemia is
an independent predictor of clinical outcome [29,30].
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